GlaxoSmithKline, Ranbaxy settle Valtrex patent dispute

Share this article:

Generics drug firm Ranbaxy Laboratories said it has reached an agreement with GlaxoSmithKline resulting in a dismissal of US patent litigation regarding Glaxo's herpes pill Valtrex (valacyclovir hydrochloride).

Under the agreement, Ranbaxy will be allowed to introduce its generic version of Valtrex in the US in late 2009 and will have 180 days of sales product exclusivity.

In early February 2007, Ranbaxy received a final approval from the FDA to market and manufacture valacyclovir hydrochloride tablets.

Glaxo's Valtrex patent is set to expire in 2009 in the US and most of Europe. The drug was first introduced in 1995.

Total global sales of Valtrex were around $1.3 billion for 2006.

 

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.